Survodutide
SYNCHRONIZE-1
Boehringer Ingelheim · Phase 3 · Completed · Enrollment 726
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- Survodutide 3.6 mg: week 76 -12.2%
- Survodutide 6.0 mg: week 76 -13%
- Placebo: week 76 -5.4%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.